Most Recent
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker's top-selling antipsychotic Abilify.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
US-based Dana-Farber Cancer Institute has succeeded in patenting a patient-specific method for developing cancer vaccines using genome sequencing.
A judge has rejected Samsung Bioepis' bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant's patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be "no more than an exercise in fishing".
Drug giant Pfizer has blasted Samsung Bioepis' “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.
Concrete repair company Vector Corrosion Technologies has lost its bid for ownership of a concrete treatment patent held by three former employees who jumped ship, with a court finding the trio invented the technology after leaving Vector.
Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.